Acosta MCM

Language: Spanish
References: 9
Page: 56-57
PDF size: 103.57 Kb.

REFERENCES

1. Meca Lallana JE, Olascoaga Urtaza J. Tratamiento de los brotes y recaídas. Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología. Madrid: Ediciones SEN; 2023. pp. 153-155.

2. Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler. 2016; 22 (10): 1337-1348.

3. Liu S, Liu X, Chen S, Xiao Y, Zhuang W. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PLoS One. 2017; 12 (11): e0188644.

4. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005; 11 (4): 425-432.

5. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020; 6 (1): 85.

6. Caster O, Edwards IR. Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol. 2015; 15: 206.

7. Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, et al. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology. 2019; 92 (13): e1507-e1516.

8. Dobson R, Hellwig K. Use of disease-modifying drugs during pregnancy and breastfeeding. Curr Opin Neurol. 2021; 34 (3): 303-311.

9. Boz C, Terzi M, Zengin Karahan S, Sen S, Sarac Y, Emrah Mavis M. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Mult Scler. 2018; 24 (9): 1205-1211.